melitac 12.1 peptide vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01264731)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- melitac 12.1 peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01961115 | Phase 2 | Sep 13, 2013 | Cancer Immunotherapy Trials Network, Incyte, National Cancer Institute (NCI), University of Virginia, University of Washington |
| NCT01264731 | Phase 1 | Jan 1, 2011 | University of Virginia |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Virginia | Academic/Hospital | 2 | 1 | 2 | 2011 |
| Cancer Immunotherapy Trials Network | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Incyte | For profit | 1 | 0 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2013 |
5 organizations
Page 1 / 1